TVRD 8-K: Fda approval
Tvardi Therapeutics
Filed with the SEC on · accession 0001104659-26-129948
TVRD filed a 8-K (current report) with the SEC on Nov 19, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Tvardi Therapeutics announced it is advancing its next-generation oral STAT3 inhibitor TTI-109 toward an IND filing for inflammatory bowel disease following positive FDA pre-IND feedback.
Key details
✦ Ask GOAX AI about this filing — what it means for TVRD, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for TVRD?
Click hereFrequently asked questions
What did TVRD file with the SEC on Nov 19, 2026?
TVRD filed a 8-K (Fda approval). Tvardi Therapeutics announced it is advancing its next-generation oral STAT3 inhibitor TTI-109 toward an IND filing for inflammatory bowel disease following positive FDA pre-IND feedback.
What does a fda approval mean for TVRD stock?
For a small biotech one drug can be most of the company’s value. Approval opens sales; a rejection (complete response letter) can delay it by years.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other TVRD SEC filings
Get alerts when TVRD files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days